

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Bessette, DC;Tilch, E;Seidens, T;Quinn, MCJ;Wiegmanns, AP;Shi, W;Cocciardi, S;McCart-Reed, A;Saunus, JM;Simpson, PT;Grimmond, SM;Lakhani, SR;Khanna, KK;Waddell, N;Al-Ejeh, F;Chenevix-Trench, G

Title:

Using the MCF10A/MCF10CA1a breast cancer progression cell line model to investigate the effect of active, mutant forms of EGFR in breast cancer development and treatment using gefitinib

Date:

2015-05-13

Citation:

Bessette, D. C., Tilch, E., Seidens, T., Quinn, M. C. J., Wiegmanns, A. P., Shi, W., Cocciardi, S., McCart-Reed, A., Saunus, J. M., Simpson, P. T., Grimmond, S. M., Lakhani, S. R., Khanna, K. K., Waddell, N., Al-Ejeh, F. & Chenevix-Trench, G. (2015). Using the MCF10A/MCF10CA1a breast cancer progression cell line model to investigate the effect of active, mutant forms of EGFR in breast cancer development and treatment using gefitinib. Plos One, 10 (5), <https://doi.org/10.1371/journal.pone.0125232>.

Persistent Link:

<https://hdl.handle.net/11343/262082>

License:

CC BY

RESEARCH ARTICLE

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib



Darrell C. Bessette^{1†}, Erik Tilch^{1†}, Tatjana Seidens¹, Michael C. J. Quinn², Adrian P. Wiegman¹, Wei Shi¹, Sibylle Cocciardi¹, Amy McCart-Reed^{1,3}, Jodi M. Saunus^{1,3}, Peter T. Simpson^{1,3}, Sean M. Grimmond², Sunil R. Lakhani^{3,4,5}, Kum Kum Khanna¹, Nic Waddell^{1,2}, Fares Al-Ejeh¹, Georgia Chenevix-Trench^{1*}

1 QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, **2** Queensland Centre for Medical Genomics, The Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia, **3** The University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australia, **4** The University of Queensland School of Medicine, Brisbane, Queensland, Australia, **5** Pathology Queensland, The Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia

OPEN ACCESS

Citation: Bessette DC, Tilch E, Seidens T, Quinn MCJ, Wiegman AP, Shi W, et al. (2015) Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PLoS ONE 10(5): e0125232. doi:10.1371/journal.pone.0125232

Academic Editor: Jung Weon Lee, Seoul National University, REPUBLIC OF KOREA

Received: July 28, 2014

Accepted: March 22, 2015

Published: May 13, 2015

Copyright: © 2015 Bessette et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All SNP Array files are available from the GEO database (accession number GSE59800).

Funding: This work was funded by the National Health and Medical Research Council Australia (Programme Grant No. 1017028). In addition, APW and PTS are funded by fellowships from the National Breast Cancer Foundation, Australia; GCT is a Senior Principal Research Fellow of the NHMRC. ET was supported by the Max Weber-Programm des

† These authors contributed equally to the manuscript.

* Georgia.Trench@qimrberghofer.edu.au

Abstract

Background

Basal-like and triple negative breast cancer (TNBC) share common molecular features, poor prognosis and a propensity for metastasis to the brain. Amplification of *epidermal growth factor receptor (EGFR)* occurs in ~50% of basal-like breast cancer, and mutations in the epidermal growth factor receptor (*EGFR*) have been reported in up to ~10% of Asian TNBC patients. In non-small cell lung cancer several different mutations in the EGFR tyrosine kinase domain confer sensitivity to receptor tyrosine kinase inhibitors, but the tumorigenic potential of EGFR mutations in breast cells and their potential for targeted therapy is unknown.

Materials and Methods

Constructs containing wild type, G719S or E746-A750 deletion mutant forms of *EGFR* were transfected into the MCF10A breast cells and their tumorigenic derivative, MCF10CA1a. The effects of EGFR over-expression and mutation on proliferation, migration, invasion, response to gefitinib, and tumour formation *in vivo* was investigated. Copy number analysis and whole exome sequencing of the MCF10A and MCF10CA1a cell lines were also performed.

Freistaates Bayern zur Hochbegabtenförderung nach dem Bayerischen Eliteförderungsgesetz of the State of Bavaria and a grant from the Deans' Office of the faculty for chemistry and pharmacy of the Ludwig-Maximilians University.

Competing Interests: The authors have declared that no competing interests exist.

Results

Mutant EGFR increased MCF10A and MCF10CA1a proliferation and MCF10A gefitinib sensitivity. The EGFR-E746-A750 deletion increased MCF10CA1a cell migration and invasion, and greatly increased MCF10CA1a xenograft tumour formation and growth. Compared to MCF10A cells, MCF10CA1a cells exhibited large regions of gain on chromosomes 3 and 9, deletion on chromosome 7, and mutations in many genes implicated in cancer.

Conclusions

Mutant EGFR enhances the oncogenic properties of MCF10A cell line, and increases sensitivity to gefitinib. Although the addition of EGFR E746-A750 renders the MCF10CA1a cells more tumourigenic *in vivo* it is not accompanied by increased gefitinib sensitivity, perhaps due to additional mutations, including the *PIK3CA* H1047R mutation, that the MCF10CA1a cell line has acquired. Screening TNBC/basal-like breast cancer for *EGFR* mutations may prove useful for directing therapy but, as in non-small cell lung cancer, accompanying mutations in *PIK3CA* may confer gefitinib resistance.

Introduction

Breast cancer is the most common cancer in women and the second most common cause of cancer death, after lung cancer, in women in Australia (<http://www.aihw.gov.au/>). The most aggressive forms of breast cancer are triple negative breast cancer (TNBC), defined histologically by the absence of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor 2 (HER2), and a subset of TNBC referred to as basal-like breast cancer, characterized by CK5/6 and/or epidermal growth factor receptor (EGFR) expression [1–3]. Both tumour types are associated with shorter disease-free and overall survival, propensity for lung and brain metastases, younger age at diagnosis, African-American descent and lack of response to endocrine or HER2-mediated therapies [4–12]. There is no targeted therapy available for these tumour types so new tools to evaluate TNBC/basal-like breast cancer are required to improve prognostic capability and to predict response to standard chemotherapy.

Mutations in the tyrosine kinase domain of epidermal growth factor receptor 1 (*EGFR*) occur in ~10–40% non-small cell lung cancers (NSCLC), with the highest incidence in patients of Asian descent [13–16]. Deletions in exon 19 and in-frame missense mutations in exon 21 account for ~90% of these mutations with other mutations in exon 18, such as G719S, accounting for the rest [17]. Several of the most common mutations found in NSCLC, including G719S or E746-A750, result in the activation of EGFR pathways and oncogenic transformation [18, 19]. Tumours harbouring these *EGFR* mutations are more sensitive to tyrosine kinase inhibitors (TKI) that target EGFR, such as gefitinib, erlotinib or cetuximab [20, 21]. Several phase III clinical trials have reported improved progression-free survival (PFS) in NSCLC patients harbouring *EGFR* mutations who are treated with gefitinib or erlotinib compared to those treated with standard chemotherapy [22–27].

More recently, mutations in *EGFR* have been identified in TNBC in up to ~11% (8/70) of Asian patients [28], although these mutations seem much rarer in European and Australian breast cancer cases, at 1.3% (3/229) and 0% (0/50), respectively [29, 30]. However, *EGFR* mutations have also been found in 1/12 brain metastases from breast and 3/9 metastases from other primary cancers, suggesting that activation of the EGFR pathway may play a role in the

metastatic development of breast cancer [20]. One of the downstream modulators of EGFR signalling *PIK3CA*, exhibits activating mutations in brain metastases from breast (2/12) and other cancers (2/9) [20]. Further, *EGFR* copy number gain, or *PTEN* loss or *PIK3CA* mutation have been shown to promote brain metastases from breast cancer [31]. As TKIs have been found to improve progression free survival (PFS) in NSCLC patients, determining the consequences of these EGFR mutations in breast cancer could be of benefit to shaping the management of disease.

MCF10A is a spontaneously immortalized, non-malignant breast cell line obtained from a patient with benign fibrocystic disease [32] and is the founder cell line of a progressively more aggressive family of breast cancer lines. These cell lines include MCF10AT1 (MCF10AT), a premalignant cell line derived from MCF10A transfected with H-Ras [33], and a set of oncogenic MCF10CA cell lines (including MCF10CA1a), which gained a *PIK3CA* H1047R activating mutation after *in vivo* passage of MCF10AT [34]. While MCF10A cells are incapable of forming tumours, MCF10AT can form tumours with an incidence of about 25% [33] and MCF10CA1a always forms tumours after subcutaneous injection into nude mice [34]. The MCF10 cell line series therefore provides a useful model to assess the oncogenic potential of genes of interest. We used the MCF10A and MCF10CA1a cell lines to assess the role of the common E746-A750 deletion (*EGFR-DEL*) mutation, and the less oncogenic *EGFR* G719S missense mutation, in promoting oncogenesis and gefitinib resistance in breast cells.

Materials and Methods

Ethics Statement

This study was conducted in strict accordance with the guidelines in the current National Health and Medical Research Council Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (*Code of Practice*), the Queensland Animal Care and Protection Act 2001 and the accompanying Animal Care and Protection Regulation 2002, and the relevant Federal and State legislation and regulations. This research was covered by Animal Ethics Committee approval from the QIMR Berghofer Medical Research Institute. All surgery was performed under 2.5% isoflurane/oxygen anesthetic, and all efforts were made to minimize suffering.

Cell lines and reagents

MCF10A (ATCC, Manassas, VA) and MCF10CA1a (gift from Pauley Robert from the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan) cells were maintained in DMEM/F12 (Invitrogen, Carlsbad, CA) supplemented with 5% horse serum (Invitrogen), 500ng/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO), 100ng/ml cholera toxin (Sigma-Aldrich), 10 µg/ml insulin (Invitrogen) and 20ng/ml epidermal growth factor (EGF, Sigma-Aldrich) ("full media"). Some assays were performed in reduced (2%) serum media in the presence or absence of EGF. Gefitinib, afatinib, docetaxol and doxorubicin were purchased from Selleck Chemicals (Houston, TX) and maintained as a 10 mM stock in dimethyl sulphoxide (DMSO). Mouse anti-β-actin, mouse anti-α-tubulin and rabbit anti-mouse HRP-conjugate antibodies were obtained from Sigma-Aldrich, mouse anti-EGFR monoclonal antibody (clone 225) was isolated from hybridoma cultures (HB-8508 from the ATCC) as previously described [35], Alexa488 conjugated rabbit anti-mouse antibody was obtained from Invitrogen, and IRDye 800CW goat anti-mouse antibody was obtained from Millenium Science (Mulgrave, Australia). Growth factor-reduced Matrigel was obtained from Invitrogen.

Transfections

The retroviral vector pBABEpuro containing either *EGFR*-WT, *EGFR*-G719S (gifts from H. Greulich), or *EGFR*-E746-A750del or no insert (empty vector) (all confirmed by sequencing) were transfected into the amphotropic packaging cell line, Phoenix (ATCC), using Lipofectamine 2000 (Invitrogen). After 48 h viral supernatant was harvested, filtered (45 µm) and used to infect MCF10A cells in the presence of 8 µg/mL polybrene (Sigma-Aldrich). Cell lines were selected with 1 µg/mL puromycin for one week (Sigma-Aldrich) and designated MCF10A *EGFR*-WT, MCF10A *EGFR*-GS and MCF10A *EGFR*-DEL, respectively. To aid in assessing tumour formation assays, MCF10A and MCF10CA1a cells were tagged with luciferase using the MSCV Luciferase PGK-hygromycin (Addgene) retroviral vector. Vector DNA was transfected into Phoenix cells as described above. Virus was harvested 48, 54, 72 and 78 post-transfection and used in sequential infection of the MCF10CA1a cells (total of 4 infections) with 8 µg/ml polybrene. Stable transfectants were selected with the addition of 200 µg/ml hygromycin (Sigma-Aldrich). The luciferase-tagged cell lines were then infected with the *EGFR*-WT, *EGFR*-G719S, *EGFR*-E746-A750del vectors and designated MCF10CA1a- *EGFR*-WT, *EGFR*-GS or *EGFR*-DEL, accordingly. MCF10CA1a cells infected with empty pBABEpuro retroviral vector (EV) were used as controls (MCF10A and MCF10CA1a-EV).

Western blotting

Three to four million cells were lysed in modified radio immunoprecipitation assay (RIPA) buffer (25 mM Tris HCl pH 7.6, 151.5 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1x Complete mini protease inhibitor (Roche, Indianapolis, IN), 1 mM PMSF) for 40 minutes on ice. The lysates were clarified by centrifugation (15 minutes at 14000 rpm). 30–40 µg of lysate was resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Immobilon, Millipore, Billerica, MA). Membranes were blocked with either 5% skim milk diluted in PBS-Tween (0.1%) or Odyssey blocking buffer (Licor Biosciences, Lincoln, NE) then incubated with anti-EGFR, anti-β-actin or anti-α-tubulin diluted in blocking buffer at 4°C overnight. The filters were incubated with secondary antibodies conjugated to horse radish peroxidase and the immunocomplexes detected with the Chemiluminescence HRP Substrate kit (Millipore) or incubated with IRDye conjugated secondary antibodies and the immunocomplexes detected by fluorescence using the Licor Odyssey Classic (Licor Biosciences).

Proliferation

Cells were seeded at a density 4000, 2000, 1000 or 500 cells per well in triplicate in 96 well plates, incubated at 37°C and proliferation monitored with the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay (Promega, Madison, WI) or using real-time imaging with the Incucyte ZOOM (Ann Arbor, MI, USA). Briefly, for the MTS assay, at the designated time points MTS was diluted 1:10 in growth media to a final concentration of 0.5 mg/ml and 100 µl added to each well. The plate was incubated for 4 hours at 37°C, the reaction stopped with the addition of SDS to a final concentration of 1% and absorbance at 490 nm read. For the Incucyte, phase contrast images of the cells were obtained every 6 hours and confluency determined using the Incucyte ZOOM software.

Drug response

Cells were seeded at a density of 4000 cells/well in duplicate or triplicate in 96 well plates and incubated overnight at 37°C in the full media with or without EGF (20 ng/ml). After 24 hours, the media was replaced with media (with or without EGF) containing serial dilutions of

gefitinib. Concentrations from 0.49–4000 nM were used for the MCF10A lines and from 7.8–125 nM for the MCF10CA1a lines in assays using the Incucyte Zoom to measure cell viability, and from 15.625–1000 nM in MTS assays. Cell viability was monitored with the MTS assay for the MCF10A cell lines as described for cell proliferation. The Incucyte ZOOM was used to monitor cell viability for the MCF10CA1a lines by monitoring cell confluency as described for cell proliferation and by monitoring the increase in dead cells. For the latter, 1–2 drops/ml of NucGreen Dead 488 Ready Probes reagent (Invitrogen) was added to the gefitinib-containing media and green fluorescent images of the cells were obtained every 6 hours with the phase contrast images. The number of green objects representing dead cells was counted using the Incucyte ZOOM software. MTS assays were also performed on the MCF10CA1a lines using serial dilutions from 1000 nM to 15.625 nM of gefitinib or afatinib or from 1000 µg/ml to 15.625 µg/ml cetuximab. Cells were seeded at 1000 cells/well in triplicate in a 96 well plate incubated overnight at 37°C in full media with EGF then washed and treated with the above drug concentrations in full media without EGF and incubated for seven days. Data was analysed in GraphPad Prism Version 6.05 (GraphPad Software, La Jolla, CA, USA) using nonlinear regression of normalized inhibitor responses and automatic outlier detection.

Combination therapy assay

The MCF10CA1a cell lines were seeded at 1000 cells/well in triplicate in a 96 well plate and incubated overnight at 37°C in full media. The next day the cells were washed and incubated in full media without EGF containing either serial dilutions of chemotherapy alone (docetaxel/doxorubicin at a 5:1 ratio—a ratio determined to minimize drug dose and maximize *in vivo* responses in a mouse model of triple negative breast cancer [35]) or chemotherapy with afatinib at its calculated ½ IC₅₀ concentrations. Cell survival was measured using the MTS assay after seven days of treatment. The concentrations used for the chemotherapy treatment were (docetaxel/doxorubicin) 10 nM/2 nM, 5/1, 2.5/0.5, 1.25/0.25, 0.625/0.125, 0.3125/0.0625, 0.15625/0.03125. For afatinib the doses of used were 41 nM (MCF10CA1a), 35 nM (MCF10CA1a-EGFR-WT), 34 nM (MCF10CA1a-EGFR-GS), and 29 nM (MCF10CA1a-EGFR-DEL), respectively.

Acini formation assays

Cells were resuspended at 1.25×10^4 cells/ml in assay media containing 2% growth factor reduced Matrigel with or without EGF (5 ng/ml), 400 µl added to 8-well chamber slides (Thermo-Scientific, Waltham, MA) pre-coated with 60 µl growth factor reduced Matrigel and incubated at 37°C. Phase contrast images were obtained on day 13 using the 4X objective of an Axiovert 135 microscope (Zeiss, Jena, Germany) and reviewed using ImageJ 1.44p software [36]. After 14 days the acini were fixed in methanol at -20°C, blocked in 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS), stained for α-tubulin diluted in 1% BSA in PBS and counterstained with DAPI (Sigma-Aldrich) in PBS-Tween 20 (0.1%). The chambers were dismantled, Prolong Gold antifade (Invitrogen) was added and coverslips were affixed to the slides. Confocal fluorescent images were taken with a Leica TCS SP2 confocal microscope (Leica Microsystems, North Ryde, Australia) using the Leica Confocal software.

Migration and invasion

For migration assays, cells were seeded in duplicate into the top chamber of a 16-well RTCA CIM Plate 16 for the xCELLigence system for real-time cellular analysis (John Morris Scientific, AUS) in serum-free media (SFM) at a density of 4×10^4 cells/well. Media containing 20 ng/ml EGF was aliquoted into the bottom chamber and the migration assessed by measuring

electrical impedance every 5 minutes for up to 78 hours. Invasion assays were performed in a similar fashion except 30 μ l of a 1:10 dilution of growth factor reduced Matrigel in SFM was aliquoted into the top chamber of each well and allowed to set at 37°C for 3–4 hours. Cells were seeded in duplicate at a density of 1×10^5 cells/well and invasion monitored as described above.

Tumour formation

MCF10A and MCF10CA1a were infected with either *EGFR*-wild type (WT), *EGFR*-G719S (GS), *EGFR*-E746-A750del (DEL) or empty vector (EV) as described above. Exponential growth phase cells (5×10^6) were collected and prepared in a 1:1 (v:v) solution of PBS/Matrigel for injection into the mammary fat pads of female BALB/c nude mice at 5–6 weeks of age. Tumour growth was monitored with bioluminescent live luciferase imaging (BLI) or calliper measurements. Tumours were surgically resected after reaching 250 mm³ in volume (calculated as: shortest diameter² x longest diameter/2) and mice were further monitored for metastatic deposits by BLI.

Genomic DNA preparation

Genomic DNA from the cell lines was extracted using the DNeasy Blood & Tissues Kit (Qiagen, Chadstone, Vic, Australia) according to manufacturer's instructions. Briefly, cells were cultured to 80–90% confluency in T-75 flasks, trypsinized, washed in PBS and lysed using following the standard protocol. The DNA was eluted in 200 μ l of the provided elution buffer and concentration determined by measuring absorbance at 260 nm on the NanoDrop 2000. gDNAs were stored at -20°C until used for exome sequencing and SNP-chip assays below.

Copy number analysis by SNP array

DNA (200ng) from the MCF10A and MCF10CA1a cell lines was analyzed for copy number alterations using Illumina Human Omni 2.5M SNP arrays (2.5–8 v1.1). Copy number was quantified and summarized using GAP [37], and copy number changes across all chromosomes for a given sample were visualized by Circos plots [38]. Copy number was classified as follows: 0 = deletion, 1 = loss, 3–5 = medium gain, and 6–8 = high level gain. The raw data was submitted to the Gene Expression Omnibus (GEO) database (accession number: GSE59800).

Exome sequencing

Exome sequencing libraries were generated using the Nextera Rapid Capture Exome (Illumina, San Diego, CA). Fifty ng of gDNA was used to generate a whole genome-sequencing library. Sequence libraries were subsequently pooled into sets of 12 prior to hybridization and enrichment. Note that all hybridizations, washes and enrichments were performed using the manufacturer's recommendation. In all cases, libraries at both the whole genome and enriched exome stages were qualified and quantified using the DNA High sensitivity assay (BioAnalyzer 2100 Agilent). Exome sequencing was performed using the Illumina 2500 HiSEQ platform. Cluster generation and sequencing was completed using TruSeq PE Cluster Kit v3-cBot-HS and TruSeq SBS Kit v3-HS (200 cycle) kits respectively with libraries clustered at 8pM using the cBOT instrument (Illumina). Three sequencing reads were generated including 101bp paired-end sequencing reads and a single index read which allows for de-multiplexing of the library pools. Clustering and sequencing were performed following the manufacturer's recommendations.

Variant calling and prediction

Sequencing data was aligned to the human genome (hg19) using BWA [39]. Cell line specific variants were identified using qSNP [40] (heuristic driven somatic/germline caller) and the Genome Analysis Tool Kit (GATK) [41] (a Bayesian caller). Only variants that were called by both qSNP and GATK were used in subsequent analyses. The Pindel tool [42] was used to identify insertion-deletion events. Cell line specific variants were subsequently annotated for gene consequence using ENSEMBL v70.

Several online tools were used to determine the effects of the rare variants discovered by exome sequencing. Either the nucleotide and/or the amino acid residue changes were entered into the PolyPhen-2 [43] and Provean [44] online software tools. The Provean online tool uses both the Provean and SIFT [45–49] algorithms to determine the pathogenicity of the mutations. The Ingenuity Pathway Analysis tool was used to assess the gene lists for potentially damaging rare variants in each line (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity).

Results

EGFR activating mutations mediate EGF-independent proliferation in MCF10A

As triple negative breast cancers (TNBC) have been found to harbour mutations in *EGFR* [28], we wished to determine how they affect a relatively normal breast cell line. We used MCF10A cells, a spontaneously immortalized, non-malignant cell line obtained from a patient with fibrocystic disease [32], and stably infected them with *EGFR*-wild type (WT), *EGFR*-G719S (GS) or *EGFR*-DEL (E746-A750) (DEL) retroviral constructs. All three constructs expressed EGFR well *in vitro* (S1 Fig). The proliferation of the MCF10A cell lines containing the *EGFR* constructs was monitored in the presence or absence of EGF (Fig 1A and 1B). Neither wild type *EGFR*, nor *EGFR* mutant expression, affected the proliferation of the MCF10A cells in the presence of EGF. However, in the absence of EGF both *EGFR*-GS and *EGFR*-DEL mutant expression resulted in increased proliferation of the MCF10A cells compared to the parental control, or the cells expressing wild type *EGFR*.

MCF10A cells expressing activated EGFR mutations are sensitive to the EGFR inhibitor, gefitinib

Several different somatic *EGFR* mutations have been shown to confer sensitivity to tyrosine kinase inhibition (TKI) in cancer models [50]. To determine whether the *EGFR*-GS or *EGFR*-DEL mutants could affect MCF10A sensitivity to TKIs, survival was monitored in the presence of a range of gefitinib concentrations in media with or without EGF (Fig 1C and 1D). MCF10A cells displayed a significant sensitization to gefitinib in EGF-free media (IC_{50} 24±8 compared to 560±20 nM in EGF containing media, $p < 0.0001$). Over-expression of wild type *EGFR* did not alter the response of MCF10A to gefitinib IC_{50} (EGF-free media: 32±3 nM; EGF containing media: 580±20 nM). In contrast, expression of either the GS or DEL mutant *EGFR* increased the sensitivity of MCF10A cells in media containing EGF (183±8 nM, $p < 5 \times 10^{-6}$; 45±5 nM, $p < 1 \times 10^{-6}$, respectively). The MCF10A *EGFR*-DEL cells, but not the MCF10A *EGFR*-GS cells (19±3 nM) were also more sensitive to gefitinib in EGF-free media (4.7±0.5 nM, $p < 0.05$).

Mutant EGFR promotes spheroid formation in MCF10A cells

Microscopic analysis of two dimensional culturing of the *EGFR* cell line derivatives revealed only minimal differences in cell morphology (S2 Fig) so acini formation was assessed to




Fig 1. Expression of the EGFR-GS and DEL mutant proteins enhances MCF10A EGF-independent growth and sensitivity to gefitinib. **A.** Cells were cultured in the presence (+ EGF) or absence (- EGF) of EGF and their proliferation assessed using MTS assay by measuring absorbance at 490 nm over a period of 8 days. **B.** The doubling times of the cell lines were calculated from the rates of proliferation. As neither MCF10A nor MCF10A-WT cell proliferated in the absence of EGF, a doubling time could not be calculated. **C.** Cells were treated with varying concentrations of gefitinib in the absence of EGF for 72 hours and cell viability measured using the MTS assay. The IC_{50} was calculated and the differences compared using the unpaired t-Test (* $p < 0.05$). **D.** Cells were treated with varying concentrations of gefitinib in the presence of EGF for 72 hours and cell viability measured using the MTS assay. The IC_{50} was calculated and the differences compared using the unpaired t-Test (**** $p < 0.0001$). 10A: MCF10A-EV, WT: MCF10A-EGFR-WT, GS: MCF10A-EGFR-GS, DEL: MCF10A-EGFR-DEL. Data from duplicate experiments.

doi:10.1371/journal.pone.0125232.g001

determine whether expression of EGFR-GS or EGFR-DEL mutants can alter acini morphology, as a marker of the oncogenic potential of MCF10A cells [51]. In the presence of EGF all four cell lines produced acinar structures of 50–100 μm size, though the acini formed by the MCF10A EGFR-GS cells tended to be more heterogenous and slightly dispersed (Fig 2). MCF10A formed acini with mostly empty luminal spaces but the acini formed by MCF10A EGFR-WT cells in the presence of EGF were also partially occluded (S3 Fig). In the absence of EGF, only MCF10A EGFR-DEL cells formed acini at a rate similar to that seen in the presence of EGF. MCF10A EGFR-GS cells formed some acini in the absence of EGF, but these were small and infrequent; MCF10A and MCF10A EGFR-WT cells did not form acinar structures in the absence of EGF (Fig 2). The luminal spaces of the acini formed by the MCF10A EGFR-GS and DEL cells were partially occluded by cells in either the presence or absence of EGF (S3 Fig). These results suggest that expression of the EGFR-DEL mutant may increase the oncogenic potential of MCF10A cells.




Fig 2. EGFR-DEL expression enhances anchorage-independent growth of MCF10A cells in the absence of EGF. Cells were cultured in media containing growth factor-reduced Matrigel with 2% horse serum in the absence (- EGF) or presence of 5 ng/ml EGF (+ EGF). At 13 days spheroid formation assessed was assessed with phase contrast microscopy. Scale bars = 400 μ m.

doi:10.1371/journal.pone.0125232.g002

Expression of EGFR-DEL increases tumourigenicity of MCF10CA1a but not MCF10A cells

EGFR-DEL and EGFR-GS expression in MCF10A cells resulted in an increased proliferative ability *in vitro* and EGFR-DEL expression could induce spheroid formation in media lacking EGF. To determine whether these changes were reflected by increased tumorigenicity *in vivo* we examined the growth of mammary fat pad xenografts of the various MCF10A EGFR cell lines. The expression of the EGFR constructs in the MCF10A cells did not induce primary tumour formation up to 6 months post-injection (data not shown). As the MCF10A cell line is not malignant and the EGFR mutants were not sufficient to induce tumourigenesis, we decided to use the MCF10A derivative cell line, MCF10CA1a. MCF10CA1a is a fully malignant cell line that gained a spontaneous PIK3CA H1047R activating mutation [34] after *in vivo* passaging of MCF10AT cells, which were derived by transfecting active mutant HRAS G12V into MCF10A cells [33]. After generating a stable luciferase-expressing MCF10CA1a cell line, the cell line was engineered to express our EGFR constructs with an empty vector (EV) serving as a control (S1 Fig). The growth of the tumours induced by the MCF10CA1a cells was significantly increased by the expression of EGFR-DEL and to a lesser extent by EGFR-GS and EGFR-WT expression compared to the MCF10CA1a-EV cells (Fig 3).

The primary tumours from the MCF10CA1a-EGFR-DEL and—GS expressing cells were surgically resected (6 weeks post injection) and the animals monitored for metastasis using bioluminescence of the tumours. Luciferase signals were only observed in the MCF10CA1a-EGFR-DEL tumour-resected mice (2 out of 5) but were lost after 6 months (S4 Fig). Similar results were observed in an independent experiment where signals were initially observed outside of the primary tumour site but disappeared after 6 months (data not shown). These luciferase signals may not be indicative of true metastatic deposits, but, rather, may be dormant deposits that failed to overcome natural killer cell activity which is known to be increased in adult nude and other athymic strains of mice compared to mice with intact immune systems [52–54].




Fig 3. Overexpression of wild type or mutant *EGFR* increases the growth of MCF10CA1a mammary fat pad xenografts. Female BALB/c nude mice were injected in the mammary fat pad with 5×10^6 cells from the indicated cell line and tumour formation was monitored with bioluminescent imaging. CA: MCF10CA1a-EV, WT: MCF10CA1a-*EGFR*-WT, GS: MCF10CA1a-*EGFR*-GS, DEL: MCF10CA1a-*EGFR*-DEL. **A.** Representative bioluminescent images of individual mice taken on day 14 and day 43. **B.** Plot of the increase in luciferase signal in each group of mice (* $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$, $n = 5$, vs CA control, One-Way ANOVA). **C.** Representative bioluminescent images of individual mice taken on day 49 post injection in an independent cohort of mice. **D.** Plot of the magnitude of luciferase signal in each group of mice at day 49 post injection (** $p < 0.01$, $n = 5$).

doi:10.1371/journal.pone.0125232.g003

EGFR mutant expression increases EGF-independent proliferation of MCF10CA1a cells but has little effect on EGFR tyrosine kinase inhibitor sensitivity

We found that MCF10CA1a cells expressing mutant *EGFR* were the more aggressive compared to EV-control cells in the *in vivo* model of tumour formation. We therefore performed further characterization *in vitro* of MCF10CA1a cells expressing wildtype or mutant *EGFR*. *EGFR*-WT (doubling time: 23.87 ± 2.27 h, $p < 0.05$), *EGFR*-GS (22.59 ± 3.04 h, $p < 0.05$) and *EGFR*-DEL (21.7 ± 1.65 h, $p < 5 \times 10^{-4}$) expressing MCF10CA1a cells demonstrated a faster proliferation rate than the MCF10CA1a-EV control cells (26.84 ± 1.06 h) in EGF-free media (Fig 4A and 4B). Treatment with high concentrations of gefitinib in the presence or absence of EGF inhibits proliferation and induces cell death (S5 Fig) in all the MCF10CA1a lines. Interestingly, none of the *EGFR* constructs affected MCF10CA1a cell proliferation sensitivity (Fig 4C) or cell death response to gefitinib in the short term Incucyte assays (Fig 4D) but both *EGFR*-WT and *EGFR*-GS constructs but not *EGFR*-DEL exhibited a trend for decreased MCF10CA1a cell survival compared to the parental cells as measured by the long term MTS assay (Fig 4E). Two other EGFR inhibitors, afatinib and the monoclonal antibody cetuximab, also induce MCF10CA1a cell death independently of wild type or mutant EGFR expression (Fig 4F and 4G).

To determine if the presence of the EGFR mutants would alter MCF10CA1a cell sensitivity to standard anthracycline/taxane-based chemotherapy we treated cells with various concentrations of the docetaxel/doxorubicin dose regimen previously used in our lab [35] combined with the half IC₅₀ dose of afatinib for each cell line (Fig 5, S6 Fig). The addition of afatinib or gefitinib (data not shown) to docetaxel/doxorubicin did not alter the sensitivity of the any of the cell lines to the chemotherapy regime.

EGFR-GS and EGFR-DEL expression increases the rate of migration and invasion of MCF10CA1a cells

A hallmark of cancer is the increased ability of cancer cells to migrate and invade through the extracellular matrix [55]. Migration and invasion of the MCF10CA1a cells containing the EGFR constructs was assessed using the xCelligence real-time monitoring system. Both MCF10CA1a *EGFR*-GS and *EGFR*-DEL cells migrated faster than the control empty vector cells (relative migration: 2.62 ± 0.85 , $p < 0.05$; 2.43 ± 0.47 , $p < 0.05$) to media containing 5% horse serum and 20ng/ml EGF after 48 hours (Fig 6A). The MCF10CA1a *EGFR*-DEL cells could invade Matrigel 1.39 ± 0.08 times faster than empty vector control cells at 48 hours ($p < 0.05$) in media containing 5% horse serum and 20ng/ml EGF (Fig 6B). These results suggest that *EGFR*-DEL and, to a lesser extent, EGFR-G719S mutations may confer metastatic properties on breast cancer cells. This was observed to some extent with the ability of the MCF10CA1A *EGFR*-DEL cells injected into mice to temporarily colonize the brain and other sites after the primary tumour removal, though true metastases were not formed (S4 Fig).

Copy number analysis and exome sequencing of MCF10A and MCF10CA1a cells

Although the exome of MCF10A has been sequenced [56], there are no published reports of the exome sequence of MCF10CA cells. We therefore sequenced the MCF10CA1a, and MCF10A cell lines, in order to determine whether additional somatic mutations in MCF10CA1a, apart from those known to have occurred in *HRAS* and *PIK3CA*, might contribute to its tumourigenicity and resistance to gefitinib. We also compared copy number variations between these two lines using Illumina Human Omni 2.5M SNP arrays. Several




Fig 4. Expression of the EGFR-GS and DEL mutant proteins enhances MCF10CA1a EGF-independent growth but not sensitivity to gefitinib. **A.** Cells were cultured in the presence (+ EGF) or absence (- EGF) of EGF and their proliferation assessed using real-time imaging on the Incucyte Zoom and measuring the increase in confluency over 4–5 days. The doubling times of the cell lines were calculated from the rates of proliferation from 36–60 hours (24 hour period). While there was no difference in proliferation between the cell lines in the presence of EGF, in the absence of EGF all three EGFR constructs reduced MCF10CA1a doubling time (*p<0.05, **** p<0.0001, unpaired T-test, n = 6). **B.** Representative growth curves for cells grown in EGF-free media with measurements of confluency taken every 6 hours for up to 102 hours. **C–D.** Calculated IC₅₀ values of gefitinib for inhibition of proliferation (**C**) or cell toxicity (**D**) from cells treated for 48 hours in various doses of gefitinib and monitored in real-time using the Incucyte Zoom (** p<0.01, unpaired T-test, n = 3). **E–G.** Calculated mean IC₅₀ values from cells treated for seven days in various doses of gefitinib (**E**, n = 2), afatinib (**F**, n = 4) or cetuximab (**G**, n = 1) and cell death determined using the MTS assay. CA: MCF10CA1a-EV, WT: MCF10CA1a-EGFR-WT, GS: MCF10CA1a-EGFR-GS, DEL: MCF10CA1a-EGFR-DEL.

doi:10.1371/journal.pone.0125232.g004




Fig 5. Docetaxel/doxorubicin chemotherapy of MCF10CA1a is unaffected by EGFR mutation or in combination with afatinib. Cells were cultured in the presence of EGF and treated with docetaxel/doxorubicin in a 5:1 ratio (DD) alone or in combination with the half IC_{50} dose of afatinib (DDA) for seven days. Cell survival was assessed using the MTS assay and the IC_{50} dose was reported using the docetaxel concentrations. CA: MCF10CA1a-EV, WT: MCF10CA1a-EGFR-WT, GS: MCF10CA1a-EGFR-GS, DEL: MCF10CA1a-EGFR-DEL.

doi:10.1371/journal.pone.0125232.g005

prominent regions of difference were found between MCF10A and MCF10CA1a, including large regions of copy number gain in chromosomes 1 and 8 in MCF10A that were missing in MCF10CA1a, and regions of gain on chromosomes 3 and 9, and regions of both gain and loss on chromosome 7 in MCF10CA1a relative to MCF10A (Fig 7). Gain of 2374 protein-coding genes and loss of 461 genes was present in MCF10A (S1 and S2 Tables) while MCF10CA1a showed gain of 1433 genes and loss in 33 genes (S2 and S3 Tables). Relative to the reference genome, gain of 544 and loss in 24 genes were found to be in common between the two cell lines (S3 Table).

We performed exome sequencing of the MCF10A and MCF10CA1a cell lines using Illumina Nextera technology and the average sequencing read depth was ~200 reads for both cell lines. The cell line specific variants were called as described and are shown in S4 and S5 Tables. The G12V *HRAS* mutation introduced into the MCF10A line to generate the precursor MCF10AT line [33] and the spontaneous H1047R *PIK3CA* mutation that arose in the MCF10CA1a line [57] were correctly identified in the MCF10CA1a cells. In total, 85 rare variants (which could be germline or somatic in origin) were identified as specific to MCF10A cells and 172 rare variants (assumed to be somatic mutations) were identified in the MCF10CA1a cells (Table 1). Of these 24/85 and 43/172 were synonymous mutations in the MCF10A and MCF10CA1a lines, respectively, with the rest potentially affecting splicing or protein coding.

Several online tools (PolyPhen-2, Provean, SIFT) were used to assess the potential effect of the rare variants on gene function (S4 and S5 Tables). PolyPhen-2 and SIFT only provide information on missense mutations but Provean provides limited information on other non-synonymous variants as well. Approximately 50% of the missense variants in both the MCF10A (26/47) and MCF10CA1a (55/98) lines were predicted to be damaging by at least two out of three software tools; a number of these variants, or the genes in which they were found, have been linked to cancers.




Fig 6. Mutant EGFR expression increases the migratory and invasive abilities of MCF10CA1a cells. A. MCF10CA1a cells expressing empty vector (CA), wild-type *EGFR* (WT), G719S *EGFR* (GS) or E746-A750 Deletion *EGFR* (DEL) were seeded in serum-free media (SFM) at 40000 cells/well in 16-well xCELLigence plates and their migration to full media containing 20 ng/ml EGF monitored. The top panel is the average of the relative migration of the cells at 48 hours of three independent experiments while the bottom panel is a representative trace from one experiment of the absolute migration index over the course of the experiment (* $p < 0.05$, unpaired T-test). **B.** MCF10CA1a cells expressing empty vector (CA), wild-type *EGFR* (WT), G719S *EGFR* (GS) or E746-A750 Deletion *EGFR* (DEL) were seeded in SFM containing Matrigel at 100000 cells/well in 16-well xCELLigence plates and their invasion to full media containing 20 ng/ml EGF monitored. The top panel is the average of the relative invasion of the cells at 48 hours of two independent experiments while the bottom panel is a representative trace from one experiment of the absolute invasion index over the course of the experiment (* $p < 0.05$, unpaired T-test).

doi:10.1371/journal.pone.0125232.g006

We analyzed the gene lists of the potentially damaging rare variants for each line using the Ingenuity Pathway Analysis to determine the key cellular functions and diseases associated with these genes (S7 Table). Cancer was a top three disease identified by IPA in both MCF10A (top disease) and MCF10CA1a (third disease). The top molecular and cellular functions were predicted to be cellular morphology in the MCF10A list and cell death and survival in the MCF10CA1a list.

Discussion

Herein we report the effect of activating mutations of *EGFR* on the tumourigenic properties of MCF10A and MCF10CA1a cells. While ectopic expression of active forms of *EGFR* did not affect either MCF10A or MCF10CA1a proliferation in the presence of EGF, it did enhance cell proliferation of both cell lines in the absence of EGF (Figs 1A and 1B and 4A and 4B). This was most apparent in the MCF10A line, which did not grow in media without EGF, even with expression of wild type *EGFR*. The presence of mutant *EGFR* also induced spheroid formation in




Fig 7. Circos plot summarizing the gene amplification and loss differences between MCF10A and MCF10CA1a. The outer band details chromosome number and position, middle band represents MCF10A and the inner band represents MCF10CA1a. In each case, values plotted are from copy number analysis of Illumina Human Omni 2.5M SNP array data. Red regions highlight gene amplification while green regions represent gene loss.

doi:10.1371/journal.pone.0125232.g007

the absence of EGF and led to spheroids with partially occluded luminal spaces (S3 Fig). However, the enhanced oncogenic properties of the mutant *EGFR* MCF10A cells did not lead to tumour formation in nude mice suggesting that *EGFR* activation is not sufficient for tumourigenicity in MCF10A cells and a second (or more) genetic alteration is required. In contrast, mutant *EGFR* expression increased invasive potential, migratory ability and the rate of xenograft tumour formation from MCF10CA1a cells significantly compared to the control

Table 1. Frequency of each class of mutations in MCF10A and MCF10CA1a cells.

Mutation type	MCF10A (%)	MCF10CA1a (%)
Missense	47 (58.0%)	98 (55.4%)
Nonsense	2 (24.7%)	10 (5.6%)
Non-stop	0 (0.0%)	1 (0.6%)
Frameshift Deletion	2 (2.4%)	2 (1.2%)
In-frame Deletion	2 (2.4%)	1 (0.6%)
Frameshift Insertion	3 (1.7%)	0(0.0%)
Splice Site	7 (8.2%)	16 (9.3%)
Synonymous	24 (29.6%)	43 (24.3%)
Total	85	172

doi:10.1371/journal.pone.0125232.t001

empty vector or wild type *EGFR*-expressing MCF10CA1a cells. Dissemination outside the primary tumour site was observed in the xenografts containing activating *EGFR* mutations. However, this distant colonisation did not develop into overt distant metastases. These *in vivo* observations are in concordance with the increased proliferation, invasion and migration we observed *in vitro* with the mutant *EGFR* MCF10CA1a cells (Fig 6).

While mutant *EGFR* did enhance the ability of MCF10CA1a cells to form tumours in nude BALB/c mice, it was unable to induce metastases after resection of the primary tumours (S4 Fig) or after intravenous injections in lung colonization experiments. MCF10CA1a has been shown to form lung metastases when injected into the tail vein of SCID/beige mice [34], so lack of metastases in this study may be due to difference in the mouse strains used. As it is known that the natural killer (NK) cell activity is greater in nude (including BALB/c) compared to thymic mice [52–54], it is possible that the lack of metastasis formation is due to enhanced NK cell activity.

Activating mutations in *EGFR*, including the G719S and E746-A750 deletion mutants used in this study, show increased sensitivity to TKIs [20, 21], so we therefore assessed the effect of the TKI gefitinib on cell proliferation in MCF10A and MCF10CA1a cells (Figs 1C and 1D; 4C and 4D and S5 Fig). MCF10A cells displayed increased sensitivity to gefitinib when expressing mutant *EGFR*. In MCF10CA1a cells, expression of *EGFR*-WT or—GS but not—DEL displayed a increase in gefitinib sensitivity in an equivalent assay. This may be due to changes in gene expression or to different somatic mutations between the MCF10A and MCF10CA1a cell lines. It is known that activating mutations in the *HRAS* homolog, *KRAS*, decrease gefitinib sensitivity in NSCLC [58, 59], and that activation of the PIK3CA pathway also reduces tyrosine kinase inhibitor sensitivity in *EGFR*-mutant lung cancers [60–63]. Furthermore, our whole exome sequencing analysis of the MCF10CA1a cells revealed a potentially damaging Y228H mutation in *ATXN2*, a gene that has been shown to affect *EGFR* trafficking via endocytic internalization [64]. Interestingly, the *ATXN2* gene has been found to be altered by copy number, mutation or expression in ~9% of breast cancers in the TCGA dataset (S6 Table) and this may be another mechanism for tumour cells to potentiate *EGFR* signalling. No changes in TKI sensitivity was observed when the cell lines were treated with the *EGFR* inhibitors with or without treatment with the clinically relevant chemotherapy 5:1 docetaxel/doxorubicin.

As the MCF10CA1a cell line is an *in vivo*-selected clonal derivative of the MCF10A cell line in the progression series, we assessed the genetic variation between the two cell lines by determining copy number and substitution/indels in each cell line. MCF10A shared large regions of copy number gain with MCF10CA1a in 5q, deletions in chromosome 9, 15p, 21p and 22p, and had a unique region of copy number gain in 1q and 8q not shared by MCF10CA1a (Fig 7).

Conversely, MCF10CA1a also displayed copy number gain at 3q, 7q and chromosome 9, copy number loss in 7p and 7q, and a deletion at Xp. In addition, several smaller regions of copy number gain and loss were identified in each cell line (S1 and S2 Tables). The copy number gains at 3q, 5q, 8q and chromosome 9, and the loss at 21p have been previously reported [65, 66] and several other smaller regions of copy number variation have been previously identified as well. The copy number gain at 1q in MCF10A cells, however, is unique to this study and several alterations found in previous studies were not identified in this study. This may be due to variation in the cultured cell populations and evolution of the MCF10A cell line.

Whole exome sequencing was performed on the MCF10A and MCF10CA1a parental cell lines to determine the nature of the somatic mutations that occurred in the progression from a relatively normal cell line (MCF10A) to a more aggressive, tumourigenic cell line (MCF10CA1a). The sequencing analysis identified both of the previously known mutations in the MCF10CA1a cells absent from the MCF10A line (G12V *HRS* and H1047R *PIK3CA*). The MCF10CA1a cells harboured approximately twice the number of cell line specific mutations than the MCF10A cells (Table 1). More of the mutations in the MCF10CA1a cells predicted to be damaging have been previously linked to cancer compared to the mutations in specific to the MCF10A cells. For example, *TP53BP2*, *CDK11A*, *MME* and *SEPT6* are mutated in MCF10CA1a cells and have strong correlations to a number of cancers [67–69].

CDK11A is a cyclin-dependent kinase [70] with roles in apoptosis [71] and may act as a tumour suppressor in neuroblastoma, melanoma and non-Hodgkin's lymphoma [72–74] but may be tumour promoting in osteosarcoma and liposarcoma [75, 76]. *MME* (CD10/CALLA), a matrix metalloendopeptidase, is a well known marker of B-cell acute lymphoblastic leukemia [77] and has also been linked to renal cell carcinoma [78]. *SEPT6* is a member of the septin family of polymerizing GTPases required for cortical organization and cytokinesis [79] and has been implicated in leukemia [80–82]. *SEPT6* also exhibits frequent mutations or copy number variations in a number of cancers, including breast (COSMIC (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic>; Catalogue of somatic mutations in cancer)). *CDK11A*, *MME* and *SEPT6* were also found to altered in 6.2%, 4.5%, and 3.7%, respectively, in a panel of 1062 breast tumours from the Cancer Genome Atlas project [83, 84], either through mutation, amplification, deletion or altered gene expression.

TP53BP2, also known as ASPP1 (apoptosis stimulating protein of p53-2), is a tumour suppressor gene that activates the pro-apoptotic functions of p53 distinctly from its cell cycle arrest functions [85, 86]. It binds to p53 and a number of other, potentially regulatory, proteins through a highly conserved C-terminal region (reviewed in [87]). Alter expression of *TP53BP2* in human tumours has been shown in a number of cancer types, including down-regulation in breast cancer [86, 88] and lung cancer [89–91]. Reduced expression of *TP53BP2* has been linked with poor distant recurrence-free survival in breast cancer patients [88] and was observed in metastatic breast cancer samples compared to non-metastatic samples [92], suggesting that *TP53BP2* may be associated with breast cancer progression. *TP53BP2* is altered in ~26% of the breast tumours from TCGA database (S6 Table) but, paradoxically, is predominantly amplified or overexpressed (<http://www.cbioportal.org/>, [83, 84]). It is possible that the T838R mutation in *TP53BP2* in MCF10CA1a cells may contribute to their malignancy, perhaps by decreasing *TP53BP2* protein activity.

A recent Phase II clinical trial was conducted examining the ability of the anti-EGFR monoclonal antibody cetuximab to treat metastatic TNBC patients, either alone or in combination with carboplatin [93]. Though most of the TNBCs had EGFR pathway activation, only a minority exhibited pathway inhibition after one to two weeks of inhibitor therapy, suggesting that EGFR-independent mechanisms are responsible for constitutive pathway activation. This was suggested to be due to EGFR downstream pathway activation and/or K-Ras activation. This

exemplifies the need to understand tumour genetic context in influencing drug sensitivity and the importance to implement precision medicine in order to overcome these issues. The differences between MCF10A and MCF10CA1a from the CNV and exome sequencing analysis identified in this study may be useful to guide future diagnostic efforts to understand EGFR inhibition sensitivity in breast cancer.

Interestingly, a naturally occurring constitutively active variant of *EGFR* with an in-frame 801 bp deletion excising most of the extracellular domain has been found in primary breast tumours [94]. This variant has been associated with cancer stem cell characteristics and can increase tumourigenicity of human breast cancer cell lines *in vitro* and *in vivo*. Stem cell-like cells in breast cancer have been suggested to be treatment resistant populations that can promote tumour recurrence [95]. The findings of this study suggest that while EGFR activating mutations are relevant to understanding the etiology and progression of breast cancer, they are insufficient to drive chemotherapeutic resistance. Other EGFR mutations may play a role in determining tumourigenicity and metastatic potential as well as conferring sensitivity to EGFR inhibition. Further investigation into how EGFR interacts with other oncogenic pathways will be important to aid the understanding and treatment of breast cancer. For example, treatment of ectopic mammary fat pad tumours in mice with a combination of chemotherapy, and PARP inhibitor and EGFR-targeted radioimmunotherapy was significantly more effective in preventing and even reversing tumour growth than single or double agent treatments [35].

A recent paper has described the resistance or sensitivity of various MCF10A mutant isogenic lines to EGFR, PI3K and mTOR inhibitors, both alone and in combination [96]. The isogenic mutations include the H1047R mutation in PIK3CA and the E746-A750 deletion in EGFR. Both of these isogenic lines demonstrated similar effects in response to gefitinib as seen in our assays with a general increase in sensitivity to the EGFR inhibitors. However, there are differences, including in the scale of the effects that may be accounted for the different models used. In our study the MCF10A lines overexpressed EGFR mutants while the isogenic lines used by Glaysher et al [96] were heterozygous and under normal promoter activity. Also, the MCF10CA1a lines used in our study have both the H1047R PIK3CA mutation and EGFR mutant overexpression. As isogenic activating mutations in PIK3CA also increase MCF10A cell sensitivity to EGFR inhibitors, this may explain the enhanced sensitivity to EGFR inhibitors exhibited by the parental and overexpression MCF10CA1a lines.

In conclusion, mutant *EGFR* can enhance some of the tumourigenic properties in the MCF10A/MCF10CA1a breast cancer progression model including proliferation, migration, invasion and tumour formation. Unlike MCF10A cells, MCF10CA1a cells did not exhibit increased sensitivity to gefitinib when expressing mutant *EGFR* suggesting that genetic context is important in determining responsiveness to EGFR inhibition. This may be due to copy number alterations or somatic mutations that occurred in the evolution of MCF10A to MCF10CA1a. Exome sequencing revealed a number of altered genes implicated in cancer that are specific to the MCF10CA1a line and which may represent alterations which, in addition to the mutation in *PIK3CA*, are required to impart tumourigenic properties upon the MCF10A line. These genes could be investigated further for their involvement in resistance to EGFR inhibition in breast cancer, and in breast cancer in general.

Supporting Information

S1 Fig. Protein expression of EGFR in overexpressing cell lines. EGFR expression was assessed by immunoblotting with anti-EGFR antibody in MCF10A (A) and MCF10CA1a (B) cell lines expressing EGFR wild-type (WT), EGFR-G719S (GS) or EGFR-E746-A750del (Del) (10A: MCF10A, CA: MCF10CA1a-EV). Equivalent loading was verified by immunoblotting

with either β -actin or α -tubulin, as indicated.
(TIF)

S2 Fig. EGFR expression in MCF10A cells does not affect cell morphology in 2D culture.

Cells were cultured in medium containing 20 ng/mL EGF and subconfluent cultures were imaged in random fields of view. Image contrasts was enhanced and equalized for visualization purposes. Scale bars = 100 μ m.

(TIF)

S3 Fig. Spheroids formed by EGFR expressing MCF10A cells have partially occluded luminal spaces.

Cells were cultured in the presence (5 ng/mL) or absence of EGF in growth factor free Matrigel containing media for 14 days. MCF10A and MCF10A EGFR-WT do not form spheres in the absence of EGF. Spheroids were fixed and stained for DAPI (blue) and α -tubulin (green) and examined by confocal microscopy. Images are sequential series of Z-stack images with numbers to indicate stack distance relative to the first image in each set. Scale bars = 100 μ m. Contrasts were enhanced for visualization purposes.

(TIF)

S4 Fig. Transient distant site colonization from MCF10CA1a-EGFR-DEL-induced primary tumours after resection does not lead to true metastasis formation in adult female BALB/c nude mice.

MCF10CA1a -EGFR-DEL-induced primary tumours from the mammary fat pad were surgically removed once tumour volume reached 250mm³ and mice were followed up by BLI and imaged at the indicated times post injection. Luciferase signals were observed outside the primary tumour site for up to 6 months but eventually disappeared.

(TIF)

S5 Fig. Dose response to EGFR inhibitors. (A-D) Cells were cultured in the absence (- EGF, A, B) or presence (+ EGF, C, D) of EGF, treated with the indicated dose of gefitinib (Gef) for 48 hours and survival assessed by monitoring changes in confluency (A, C) or cell death (B, D) using real-time imaging on the Incucyte Zoom. (E-F) Cells were cultured in EGF-free media, treated with the indicated dose of gefitinib (Gef), afatinib (Afata), or cetuximab (Cet) for seven days and cell death measured using the MTS assay. Shown are data representative of the results from two to four independent experiments. CA: MCF10CA1a-EV, WT: MCF10CA1a-EGFR-WT, GS: MCF10CA1a-EGFR-GS, DEL: MCF10CA1a-EGFR-DEL.

(TIF)

S6 Fig. Dose response curves to EGFR inhibitors combined with chemotherapy. Cells were cultured in the EGF-free media, treated with the indicated dose of docetaxel/ doxorubicin (5:1 ratio docetaxel:doxorubicin) either alone (DD), or with the half IC50 dose of gefitinib (DDG) or afatinib (DDA) for seven days and survival measured using the MTS assay. A. MCF10CA1a-EV. B. MCF10CA1a-EGFR-WT. C. MCF10CA1a-EGFR-GS. D. MCF10CA1a-EGFR-DEL. Data shown are representative of the results from three independent experiments.

(TIF)

S1 Table. Regions of copy number variation in MCF10A cells.

(XLSX)

S2 Table. Regions of copy number variation in MCF10CA1a cells.

(XLSX)

S3 Table. Summary of genes with copy number variations in MCF10A and MCF10CA1a.

(XLSX)

S4 Table. Single nucleotide variations and INDELs in the genome of MCF10CA1a.
(XLSX)

S5 Table. Single nucleotide variations and INDELs in the genome of MCF10A.
(XLSX)

S6 Table. Frequency of genes with potentially damaging* rare variants in MCF10CA1a are altered in breast cancer in The Cancer Genome Atlas (TCGA) dataset.** These results are based upon data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>.
* Potentially damaging mutations include missense mutations with predicted damaging effects, nonsense mutations and out-of-frame indels. ** Alterations are the total of the copy number variations, somatic mutations and gene expression changes reported in the TCGA dataset.
Total number of tumours in dataset = 1061.
(XLSX)

S7 Table. Top diseases and molecular functions for the gene list of MCF10A and MCF10CA damaging variants from Ingenuity Pathway Analysis.
(XLSX)

Acknowledgments

The authors would like to thank H. Greulich for providing critical reagents the pBABEpuro retroviral vectors containing the EGFR wild type and G719S mutant constructs and Pauley Roberts (Barbara Ann Karmons Cancer Institute, Detroit, Michigan) for providing the MCF10A series of cell lines.

Author Contributions

Conceived and designed the experiments: DCB ET TS MCJ FAE KKK NW GCT. Performed the experiments: DCB ET TS MCJ FAE WS SC. Analyzed the data: DCB ET MCJ FAE. Contributed reagents/materials/analysis tools: SRL KKK SMG NW GCT. Wrote the paper: DCB ET MCJ FAE WS AMR JMS APW PTS KKK NW GCT. Obtained permission for the use of the MCF10CA1a cell line: KK.

References

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A*. 2001; 98(19):10869–74. doi: [10.1073/pnas.191367098](https://doi.org/10.1073/pnas.191367098) PMID: [11553815](https://pubmed.ncbi.nlm.nih.gov/11553815/); PubMed Central PMCID: PMC58566.
2. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012; 490(7418):61–70. doi: [10.1038/nature11412](https://doi.org/10.1038/nature11412) PMID: [23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/); PubMed Central PMCID: PMC3465532.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature*. 2000; 406(6797):747–52. doi: [10.1038/35021093](https://doi.org/10.1038/35021093) PMID: [10963602](https://pubmed.ncbi.nlm.nih.gov/10963602/).
4. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. *J Clin Pathol*. 2006; 59(7):729–35. doi: [10.1136/jcp.2005.033043](https://doi.org/10.1136/jcp.2005.033043) PMID: [16556664](https://pubmed.ncbi.nlm.nih.gov/16556664/); PubMed Central PMCID: PMC1860434.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA*. 2006; 295(21):2492–502. doi: [10.1001/jama.295.21.2492](https://doi.org/10.1001/jama.295.21.2492) PMID: [16757721](https://pubmed.ncbi.nlm.nih.gov/16757721/).
6. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. *Clin Cancer Res*. 2008; 14(5):1368–76. doi: [10.1158/1078-0432.CCR-07-1658](https://doi.org/10.1158/1078-0432.CCR-07-1658) PMID: [18316557](https://pubmed.ncbi.nlm.nih.gov/18316557/).
7. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Modern pathology: an official journal of the United*

- States and Canadian Academy of Pathology, Inc. 2006; 19(2):264–71. doi: [10.1038/modpathol.3800528](https://doi.org/10.1038/modpathol.3800528) PMID: [16341146](https://pubmed.ncbi.nlm.nih.gov/16341146/).
8. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res*. 2004; 10(16):5367–74. doi: [10.1158/1078-0432.CCR-04-0220](https://doi.org/10.1158/1078-0432.CCR-04-0220) PMID: [15328174](https://pubmed.ncbi.nlm.nih.gov/15328174/).
9. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. *Eur J Cancer*. 2006; 42(18):3149–56. doi: [10.1016/j.ejca.2006.08.015](https://doi.org/10.1016/j.ejca.2006.08.015) PMID: [17055256](https://pubmed.ncbi.nlm.nih.gov/17055256/).
10. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clin Cancer Res*. 2009; 15(7):2302–10. doi: [10.1158/1078-0432.CCR-08-2132](https://doi.org/10.1158/1078-0432.CCR-08-2132) PMID: [19318481](https://pubmed.ncbi.nlm.nih.gov/19318481/).
11. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. *Histopathology*. 2006; 49(1):22–34. doi: [10.1111/j.1365-2559.2006.02453.x](https://doi.org/10.1111/j.1365-2559.2006.02453.x) PMID: [16842243](https://pubmed.ncbi.nlm.nih.gov/16842243/).
12. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. *Breast Cancer Res*. 2007; 9(1):R4. doi: [10.1186/bcr1636](https://doi.org/10.1186/bcr1636) PMID: [17217540](https://pubmed.ncbi.nlm.nih.gov/17217540/); PubMed Central PMCID: PMC1851397.
13. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A*. 2004; 101(36):13306–11. doi: [10.1073/pnas.0405220101](https://doi.org/10.1073/pnas.0405220101) PMID: [15329413](https://pubmed.ncbi.nlm.nih.gov/15329413/); PubMed Central PMCID: PMC516528.
14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst*. 2005; 97(5):339–46. doi: [10.1093/jnci/dji055](https://doi.org/10.1093/jnci/dji055) PMID: [15741570](https://pubmed.ncbi.nlm.nih.gov/15741570/).
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *The New England journal of medicine*. 2004; 350(21):2129–39. doi: [10.1056/NEJMoa040938](https://doi.org/10.1056/NEJMoa040938) PMID: [15118073](https://pubmed.ncbi.nlm.nih.gov/15118073/).
16. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004; 304(5676):1497–500. doi: [10.1126/science.1099314](https://doi.org/10.1126/science.1099314) PMID: [15118125](https://pubmed.ncbi.nlm.nih.gov/15118125/).
17. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. *The FEBS journal*. 2010; 277(2):301–8. doi: [10.1111/j.1742-4658.2009.07448.x](https://doi.org/10.1111/j.1742-4658.2009.07448.x) PMID: [19922469](https://pubmed.ncbi.nlm.nih.gov/19922469/).
18. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science*. 2004; 305(5687):1163–7. doi: [10.1126/science.1101637](https://doi.org/10.1126/science.1101637) PMID: [15284455](https://pubmed.ncbi.nlm.nih.gov/15284455/).
19. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. *PLoS medicine*. 2005; 2(11):e313. doi: [10.1371/journal.pmed.0020313](https://doi.org/10.1371/journal.pmed.0020313) PMID: [16187797](https://pubmed.ncbi.nlm.nih.gov/16187797/); PubMed Central PMCID: PMC1240052.
20. Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. *Breast Cancer Res*. 2010; 12(4):R46. doi: [10.1186/bcr2603](https://doi.org/10.1186/bcr2603) PMID: [20604919](https://pubmed.ncbi.nlm.nih.gov/20604919/); PubMed Central PMCID: PMC2949633.
21. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. *Cancer Res*. 2005; 65(1):226–35. PMID: [15665299](https://pubmed.ncbi.nlm.nih.gov/15665299/).
22. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *The lancet oncology*. 2010; 11(2):121–8. doi: [10.1016/S1470-2045\(09\)70364-X](https://doi.org/10.1016/S1470-2045(09)70364-X) PMID: [20022809](https://pubmed.ncbi.nlm.nih.gov/20022809/).
23. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *The New England journal of medicine*. 2010; 362(25):2380–8. doi: [10.1056/NEJMoa0909530](https://doi.org/10.1056/NEJMoa0909530) PMID: [20573926](https://pubmed.ncbi.nlm.nih.gov/20573926/).
24. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *The New England journal of medicine*. 2009; 361(10):947–57. doi: [10.1056/NEJMoa0810699](https://doi.org/10.1056/NEJMoa0810699) PMID: [19692680](https://pubmed.ncbi.nlm.nih.gov/19692680/).
25. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung

- cancer in Asia (IPASS). *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2011; 29(21):2866–74. doi: [10.1200/JCO.2010.33.4235](https://doi.org/10.1200/JCO.2010.33.4235) PMID: [21670455](https://pubmed.ncbi.nlm.nih.gov/21670455/).
26. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *The lancet oncology*. 2011; 12(8):735–42. doi: [10.1016/S1470-2045\(11\)70184-X](https://doi.org/10.1016/S1470-2045(11)70184-X) PMID: [21783417](https://pubmed.ncbi.nlm.nih.gov/21783417/).
27. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EORTAC): a multicentre, open-label, randomised phase 3 trial. *The lancet oncology*. 2012; 13(3):239–46. doi: [10.1016/S1470-2045\(11\)70393-X](https://doi.org/10.1016/S1470-2045(11)70393-X) PMID: [22285168](https://pubmed.ncbi.nlm.nih.gov/22285168/).
28. Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. *Breast Cancer Res*. 2011; 13(2):R35. doi: [10.1186/bcr2857](https://doi.org/10.1186/bcr2857) PMID: [21457545](https://pubmed.ncbi.nlm.nih.gov/21457545/); PubMed Central PMCID: PMC3219198.
29. Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, Bibeau F, et al. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. *Breast Cancer Res*. 2011; 13(6):R133. doi: [10.1186/bcr3079](https://doi.org/10.1186/bcr3079) PMID: [22192147](https://pubmed.ncbi.nlm.nih.gov/22192147/); PubMed Central PMCID: PMC3326575.
30. Tilch E, Seidens T, Cocciardi S, Reid LE, Byrne D, Simpson PT, et al. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. *Breast Cancer Res Treat*. 2014; 143(2):385–92. doi: [10.1007/s10549-013-2798-1](https://doi.org/10.1007/s10549-013-2798-1) PMID: [24318467](https://pubmed.ncbi.nlm.nih.gov/24318467/).
31. Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, et al. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. *Am J Pathol*. 2013; 183(1):83–95. doi: [10.1016/j.ajpath.2013.03.023](https://doi.org/10.1016/j.ajpath.2013.03.023) PMID: [23665199](https://pubmed.ncbi.nlm.nih.gov/23665199/).
32. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr., Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. *Cancer Res*. 1990; 50(18):6075–86. PMID: [1975513](https://pubmed.ncbi.nlm.nih.gov/1975513/).
33. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. *Am J Pathol*. 1996; 148(1):313–9. PMID: [8546221](https://pubmed.ncbi.nlm.nih.gov/8546221/); PubMed Central PMCID: PMC1861604.
34. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. *Breast Cancer Res Treat*. 2001; 65(2):101–10. PMID: [11261825](https://pubmed.ncbi.nlm.nih.gov/11261825/).
35. Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, et al. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*. 2013; 54(6):913–21. doi: [10.2967/jnumed.112.111534](https://doi.org/10.2967/jnumed.112.111534) PMID: [23564760](https://pubmed.ncbi.nlm.nih.gov/23564760/).
36. Abràmoff DMD, Magalhães DPJ, Ram DSJ. Image Processing with ImageJ. *Biophotonics International*. 2004; 11(7):36–42.
37. Popova T, Manie E, Stoppa-Lyonnet D, Rigai G, Barillot E, Stern MH. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. *Genome Biol*. 2009; 10(11):R128. doi: [10.1186/gb-2009-10-11-r128](https://doi.org/10.1186/gb-2009-10-11-r128) PMID: [19903341](https://pubmed.ncbi.nlm.nih.gov/19903341/); PubMed Central PMCID: PMC2810663.
38. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. *Genome research*. 2009; 19(9):1639–45. doi: [10.1101/gr.092759.109](https://doi.org/10.1101/gr.092759.109) PMID: [19541911](https://pubmed.ncbi.nlm.nih.gov/19541911/); PubMed Central PMCID: PMC2752132.
39. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009; 25(14):1754–60. doi: [10.1093/bioinformatics/btp324](https://doi.org/10.1093/bioinformatics/btp324) PMID: [19451168](https://pubmed.ncbi.nlm.nih.gov/19451168/); PubMed Central PMCID: PMC2705234.
40. Kassahn KS, Holmes O, Nones K, Patch AM, Miller DK, Christ AN, et al. Somatic point mutation calling in low cellularity tumors. *PLoS One*. 2013; 8(11):e74380. doi: [10.1371/journal.pone.0074380](https://doi.org/10.1371/journal.pone.0074380) PMID: [24250782](https://pubmed.ncbi.nlm.nih.gov/24250782/); PubMed Central PMCID: PMC3826759.
41. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome research*. 2010; 20(9):1297–303. doi: [10.1101/gr.107524.110](https://doi.org/10.1101/gr.107524.110) PMID: [20644199](https://pubmed.ncbi.nlm.nih.gov/20644199/); PubMed Central PMCID: PMC2928508.
42. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics*. 2009; 25(21):2865–71. doi: [10.1093/bioinformatics/btp394](https://doi.org/10.1093/bioinformatics/btp394) PMID: [19561018](https://pubmed.ncbi.nlm.nih.gov/19561018/); PubMed Central PMCID: PMC2781750.

43. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nature methods*. 2010; 7(4):248–9. doi: [10.1038/nmeth0410-248](https://doi.org/10.1038/nmeth0410-248) PMID: [20354512](https://pubmed.ncbi.nlm.nih.gov/20354512/); PubMed Central PMCID: PMC2855889.
44. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. *PLoS One*. 2012; 7(10):e46688. doi: [10.1371/journal.pone.0046688](https://doi.org/10.1371/journal.pone.0046688) PMID: [23056405](https://pubmed.ncbi.nlm.nih.gov/23056405/); PubMed Central PMCID: PMC3466303.
45. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nature protocols*. 2009; 4(7):1073–81. doi: [10.1038/nprot.2009.86](https://doi.org/10.1038/nprot.2009.86) PMID: [19561590](https://pubmed.ncbi.nlm.nih.gov/19561590/).
46. Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. *Annual review of genomics and human genetics*. 2006; 7:61–80. doi: [10.1146/annurev.genom.7.080505.115630](https://doi.org/10.1146/annurev.genom.7.080505.115630) PMID: [16824020](https://pubmed.ncbi.nlm.nih.gov/16824020/).
47. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res*. 2003; 31(13):3812–4. PMID: [12824425](https://pubmed.ncbi.nlm.nih.gov/12824425/); PubMed Central PMCID: PMC168916.
48. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. *Genome research*. 2002; 12(3):436–46. doi: [10.1101/gr.212802](https://doi.org/10.1101/gr.212802) PMID: [11875032](https://pubmed.ncbi.nlm.nih.gov/11875032/); PubMed Central PMCID: PMC155281.
49. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. *Genome research*. 2001; 11(5):863–74. doi: [10.1101/gr.176601](https://doi.org/10.1101/gr.176601) PMID: [11337480](https://pubmed.ncbi.nlm.nih.gov/11337480/); PubMed Central PMCID: PMC311071.
50. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. *Cancer science*. 2007; 98(12):1817–24. doi: [10.1111/j.1349-7006.2007.00607.x](https://doi.org/10.1111/j.1349-7006.2007.00607.x) PMID: [17888036](https://pubmed.ncbi.nlm.nih.gov/17888036/).
51. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods*. 2003; 30(3):256–68. PMID: [12798140](https://pubmed.ncbi.nlm.nih.gov/12798140/).
52. Richie JP, McDonald J, Gittes RF. Resistance to intravenous tumor metastases in the athymic nude mouse: a paradoxical response. *Surgery*. 1981; 90(2):214–20. PMID: [7256537](https://pubmed.ncbi.nlm.nih.gov/7256537/).
53. Hanna N. Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of natural killer cell-mediated cytotoxicity. *Int J Cancer*. 1980; 26(5):675–80. PMID: [6972360](https://pubmed.ncbi.nlm.nih.gov/6972360/).
54. Buckle AM, Goepel JR, Rees RC. The effect of the immune status of the TAR mouse on the growth and metastasis of tumour xenografts. *European journal of cancer & clinical oncology*. 1987; 23(6):663–74. PMID: [3308478](https://pubmed.ncbi.nlm.nih.gov/3308478/).
55. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144(5):646–74. doi: [10.1016/j.cell.2011.02.013](https://doi.org/10.1016/j.cell.2011.02.013) PMID: [21376230](https://pubmed.ncbi.nlm.nih.gov/21376230/).
56. Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, et al. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. *PLoS One*. 2011; 6(2):e17490. doi: [10.1371/journal.pone.0017490](https://doi.org/10.1371/journal.pone.0017490) PMID: [21364760](https://pubmed.ncbi.nlm.nih.gov/21364760/); PubMed Central PMCID: PMC3045451.
57. Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. *Cancer Res*. 2009; 69(18):7357–65. doi: [10.1158/0008-5472.CAN-09-0064](https://doi.org/10.1158/0008-5472.CAN-09-0064) PMID: [19706770](https://pubmed.ncbi.nlm.nih.gov/19706770/); PubMed Central PMCID: PMC2745517.
58. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2006; 24(10):1612–9. doi: [10.1200/JCO.2005.03.4900](https://doi.org/10.1200/JCO.2005.03.4900) PMID: [16575012](https://pubmed.ncbi.nlm.nih.gov/16575012/).
59. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruijff FA, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. *Int J Cancer*. 2006; 118(1):209–14. doi: [10.1002/ijc.21290](https://doi.org/10.1002/ijc.21290) PMID: [16003751](https://pubmed.ncbi.nlm.nih.gov/16003751/).
60. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. *The Journal of clinical investigation*. 2006; 116(10):2695–706. doi: [10.1172/JCI28656](https://doi.org/10.1172/JCI28656) PMID: [16906227](https://pubmed.ncbi.nlm.nih.gov/16906227/); PubMed Central PMCID: PMC1570180.
61. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. *Cancer Res*. 2009; 69(8):3256–61. doi: [10.1158/0008-5472.CAN-08-4055](https://doi.org/10.1158/0008-5472.CAN-08-4055) PMID: [19351834](https://pubmed.ncbi.nlm.nih.gov/19351834/); PubMed Central PMCID: PMC2849653.
62. Fidler MJ, Morrison LE, Basu S, Buckingham L, Walters K, Batus M, et al. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. *Br J*

- Cancer. 2011; 105(12):1920–6. doi: [10.1038/bjc.2011.494](https://doi.org/10.1038/bjc.2011.494) PMID: [22095222](https://pubmed.ncbi.nlm.nih.gov/22095222/); PubMed Central PMCID: PMC3251891.
63. Ji W, Choi CM, Rho JK, Jang SJ, Park YS, Chun SM, et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. *BMC Cancer*. 2013; 13:606. doi: [10.1186/1471-2407-13-606](https://doi.org/10.1186/1471-2407-13-606) PMID: [24369725](https://pubmed.ncbi.nlm.nih.gov/24369725/); PubMed Central PMCID: PMC3877961.
64. Nonis D, Schmidt MH, van de Loo S, Eich F, Dikic I, Nowock J, et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. *Cellular signalling*. 2008; 20(10):1725–39. doi: [10.1016/j.cellsig.2008.05.018](https://doi.org/10.1016/j.cellsig.2008.05.018) PMID: [18602463](https://pubmed.ncbi.nlm.nih.gov/18602463/).
65. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. *PLoS One*. 2010; 5(2):e9201. doi: [10.1371/journal.pone.0009201](https://doi.org/10.1371/journal.pone.0009201) PMID: [20169162](https://pubmed.ncbi.nlm.nih.gov/20169162/); PubMed Central PMCID: PMC2821407.
66. Marella NV, Malyavantham KS, Wang J, Matsui S, Liang P, Berezney R. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. *Cancer Res*. 2009; 69(14):5946–53. doi: [10.1158/0008-5472.CAN-09-0420](https://doi.org/10.1158/0008-5472.CAN-09-0420) PMID: [19584277](https://pubmed.ncbi.nlm.nih.gov/19584277/); PubMed Central PMCID: PMC2826242.
67. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res*. 2011; 39(Database issue): D945–50. doi: [10.1093/nar/gkq929](https://doi.org/10.1093/nar/gkq929) PMID: [20952405](https://pubmed.ncbi.nlm.nih.gov/20952405/); PubMed Central PMCID: PMC3013785.
68. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. *Nucleic Acids Res*. 2010; 38(Database issue):D652–7. doi: [10.1093/nar/gkp995](https://doi.org/10.1093/nar/gkp995) PMID: [19906727](https://pubmed.ncbi.nlm.nih.gov/19906727/); PubMed Central PMCID: PMC2808858.
69. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). *Current protocols in human genetics / editorial board, Jonathan L Haines [et al]*. 2008; Chapter 10:Unit 10 1. doi: [10.1002/0471142905.hg1011s57](https://doi.org/10.1002/0471142905.hg1011s57) PMID: [18428421](https://pubmed.ncbi.nlm.nih.gov/18428421/); PubMed Central PMCID: PMC2705836.
70. Kidd VJ, Luo W, Xiang JL, Tu F, Easton J, McCune S, et al. Regulated expression of a cell division control-related protein kinase during development. *Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research*. 1991; 2(2):85–93. PMID: [2069872](https://pubmed.ncbi.nlm.nih.gov/2069872/).
71. Lahti JM, Xiang J, Heath LS, Campana D, Kidd VJ. PITSLRE protein kinase activity is associated with apoptosis. *Molecular and cellular biology*. 1995; 15(1):1–11. PMID: [7528324](https://pubmed.ncbi.nlm.nih.gov/7528324/); PubMed Central PMCID: PMC231901.
72. Lahti JM, Valentine M, Xiang J, Jones B, Amann J, Grenet J, et al. Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. *Nat Genet*. 1994; 7(3):370–5. doi: [10.1038/ng0794-370](https://doi.org/10.1038/ng0794-370) PMID: [7920654](https://pubmed.ncbi.nlm.nih.gov/7920654/).
73. Dave BJ, Pickering DL, Hess MM, Weisenburger DD, Armitage JO, Sanger WG. Deletion of cell division cycle 2-like 1 gene locus on 1p36 in non-Hodgkin lymphoma. *Cancer genetics and cytogenetics*. 1999; 108(2):120–6. PMID: [9973938](https://pubmed.ncbi.nlm.nih.gov/9973938/).
74. Nelson MA, Ariza ME, Yang JM, Thompson FH, Taetle R, Trent JM, et al. Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. *Cancer genetics and cytogenetics*. 1999; 108(2):91–9. PMID: [9973934](https://pubmed.ncbi.nlm.nih.gov/9973934/).
75. Jia B, Choy E, Cote G, Harmon D, Ye S, Kan Q, et al. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. *Cancer Lett*. 2014; 342(1):104–12. doi: [10.1016/j.canlet.2013.08.040](https://doi.org/10.1016/j.canlet.2013.08.040) PMID: [24007862](https://pubmed.ncbi.nlm.nih.gov/24007862/).
76. Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, et al. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. *Clin Cancer Res*. 2012; 18(17):4580–8. doi: [10.1158/1078-0432.CCR-12-1157](https://doi.org/10.1158/1078-0432.CCR-12-1157) PMID: [22791884](https://pubmed.ncbi.nlm.nih.gov/22791884/).
77. Pesando JM, Ritz J, Lazarus H, Costello SB, Sallan S, Schlossman SF. Leukemia-associated antigens in ALL. *Blood*. 1979; 54(6):1240–8. PMID: [389310](https://pubmed.ncbi.nlm.nih.gov/389310/).
78. Holm-Nielsen P, Pallesen G. Expression of segment-specific antigens in the human nephron and in renal epithelial tumors. *APMIS Supplementum*. 1988; 4:48–55. PMID: [2465011](https://pubmed.ncbi.nlm.nih.gov/2465011/).
79. Kinoshita M, Noda M. Roles of septins in the mammalian cytokinesis machinery. *Cell structure and function*. 2001; 26(6):667–70. PMID: [11942624](https://pubmed.ncbi.nlm.nih.gov/11942624/).
80. Borkhardt A, Teigler-Schlegel A, Fuchs U, Keller C, Konig M, Harbott J, et al. An ins(X;11)(q24;q23) fuses the MLL and the Septin 6/KIAA0128 gene in an infant with AML-M2. *Genes Chromosomes Cancer*. 2001; 32(1):82–8. doi: [10.1002/gcc.1169](https://doi.org/10.1002/gcc.1169) PMID: [11477664](https://pubmed.ncbi.nlm.nih.gov/11477664/).
81. Ono R, Taki T, Taketani T, Kawaguchi H, Taniwaki M, Okamura T, et al. SEPTIN6, a human homologue to mouse Septin6, is fused to MLL in infant acute myeloid leukemia with complex chromosomal abnormalities involving 11q23 and Xq24. *Cancer Res*. 2002; 62(2):333–7. PMID: [11809673](https://pubmed.ncbi.nlm.nih.gov/11809673/).

82. Slater DJ, Hilgenfeld E, Rappaport EF, Shah N, Meek RG, Williams WR, et al. MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site. *Oncogene*. 2002; 21(30):4706–14. doi: [10.1038/sj.onc.1205572](https://doi.org/10.1038/sj.onc.1205572) PMID: [12096348](https://pubmed.ncbi.nlm.nih.gov/12096348/).
83. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer discovery*. 2012; 2(5):401–4. doi: [10.1158/2159-8290.CD-12-0095](https://doi.org/10.1158/2159-8290.CD-12-0095) PMID: [22588877](https://pubmed.ncbi.nlm.nih.gov/22588877/); PubMed Central PMCID: PMC3956037.
84. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Science signaling*. 2013; 6(269):pl1. doi: [10.1126/scisignal.2004088](https://doi.org/10.1126/scisignal.2004088) PMID: [23550210](https://pubmed.ncbi.nlm.nih.gov/23550210/).
85. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. *Molecular and cellular biology*. 2004; 24(3):1341–50. PMID: [14729977](https://pubmed.ncbi.nlm.nih.gov/14729977/); PubMed Central PMCID: PMC321425.
86. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al. ASPP proteins specifically stimulate the apoptotic function of p53. *Molecular cell*. 2001; 8(4):781–94. PMID: [11684014](https://pubmed.ncbi.nlm.nih.gov/11684014/).
87. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. *Br J Cancer*. 2007; 96(2):196–200. doi: [10.1038/sj.bjc.6603525](https://doi.org/10.1038/sj.bjc.6603525) PMID: [17211478](https://pubmed.ncbi.nlm.nih.gov/17211478/); PubMed Central PMCID: PMC2359998.
88. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. *Clin Cancer Res*. 2005; 11(24 Pt 1):8623–31. doi: [10.1158/1078-0432.CCR-05-0735](https://doi.org/10.1158/1078-0432.CCR-05-0735) PMID: [16361546](https://pubmed.ncbi.nlm.nih.gov/16361546/).
89. Mori T, Okamoto H, Takahashi N, Ueda R, Okamoto T. Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. *FEBS letters*. 2000; 465(2–3):124–8. PMID: [10631318](https://pubmed.ncbi.nlm.nih.gov/10631318/).
90. Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. *Cancer*. 2004; 100(8):1673–82. doi: [10.1002/cncr.20164](https://doi.org/10.1002/cncr.20164) PMID: [15073856](https://pubmed.ncbi.nlm.nih.gov/15073856/).
91. Li S, Shi G, Yuan H, Zhou T, Zhang Q, Zhu H, et al. Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP. *Oncology reports*. 2012; 28(1):133–40. doi: [10.3892/or.2012.1778](https://doi.org/10.3892/or.2012.1778) PMID: [22552744](https://pubmed.ncbi.nlm.nih.gov/22552744/).
92. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr., Elkahoul AG. In vivo gene expression profile analysis of human breast cancer progression. *Cancer Res*. 1999; 59(22):5656–61. PMID: [10582678](https://pubmed.ncbi.nlm.nih.gov/10582678/).
93. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2012; 30(21):2615–23. doi: [10.1200/JCO.2010.34.5579](https://doi.org/10.1200/JCO.2010.34.5579) PMID: [22665533](https://pubmed.ncbi.nlm.nih.gov/22665533/); PubMed Central PMCID: PMC3413275.
94. Del Vecchio CA, Jensen KC, Nitta RT, Shain AH, Giacomini CP, Wong AJ. Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. *Cancer Res*. 2012; 72(10):2657–71. doi: [10.1158/0008-5472.CAN-11-2656](https://doi.org/10.1158/0008-5472.CAN-11-2656) PMID: [22419663](https://pubmed.ncbi.nlm.nih.gov/22419663/).
95. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. *Carcinogenesis*. 2011; 32(5):650–8. doi: [10.1093/carcin/bgr028](https://doi.org/10.1093/carcin/bgr028) PMID: [21310941](https://pubmed.ncbi.nlm.nih.gov/21310941/).
96. Glaysher S, Bolton LM, Johnson P, Torrance C, Cree IA. Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model. *BMC research notes*. 2014; 7:397. doi: [10.1186/1756-0500-7-397](https://doi.org/10.1186/1756-0500-7-397) PMID: [24964744](https://pubmed.ncbi.nlm.nih.gov/24964744/); PubMed Central PMCID: PMC4080989.